East Rutherford-based Cambrex Corp., a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients, announced Tuesday is has completed a pilot plant expansion at its High Point, North Carolina-based facility.
The expansion includes the installation and commissioning of a fourth reactor suite, increasing the site’s reactor capacity by approximately 30 percent. The new 400-square-foot suite includes two 2,000 liter glass lined reactors and a 0.6-square-meter filter dryer. The site also completed an upgrade to its analytical chromatography data systems to Empower 3 software.
Cambrex also announced it has finished the foundation and steel-work for a new $24 million facility at its Charles City, Iowa plant.
“Both of these U.S. investments will enhance Cambrex’s cGMP capabilities and offer our customers expanded technologies and services,” said Shawn Cavanagh, chief operating officer of Cambrex. “We will continue to strategically invest across our global network of sites at all scales, from clinical through to commercial, to address customer demands and market requirements.”